A significant survival improvement finding for adults with newly diagnosed BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia appears in the New England Journal of Medicine. The practice ...

Patient 1 relapsed 4.5 months after a matched sibling donor transplant, treated with three cycles of salvage chemotherapy with two DLI with persistent marrow disease (7% blasts) before starting ...

Discover comprehensive details about Blinatumomab, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

COPENHAGEN, Denmark ― Monotherapy with the novel antibody blinatumomab (Blincyto, Amgen Inc) beat standard chemotherapy, significantly improving overall survival in adult patients with ...

The US Food and Drug Administration (FDA) has granted full approval to blinatumomab (Blincyto, Amgen) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

Blinatumomab addition to chemotherapy significantly improves survival and reduces relapse in pediatric B-cell acute lymphoblastic leukemia, especially in high-risk groups. The trial demonstrated that ...

Although adults with ALL achieve high rates of complete remission (CR) of 90% with frontline modern chemotherapy regimens, approximately 40% to 50% relapse. The overall response rates after relapse ...

Please provide your email address to receive an email when new articles are posted on . The addition of blinatumomab to chemotherapy improved DFS for children with B-cell ALL. Researchers stopped ...

Multiple immunomodulatory therapies have emerged for B-cell acute lymphoblastic leukemia (B-ALL) treatment, changing the paradigm for relapsed or refractory disease. In a multicenter, retrospective ...

Replacing two high-dose chemotherapy courses with blinatumomab (Blincyto) significantly improved event-free survival (EFS) in pediatric patients with newly diagnosed high-risk B-cell acute ...